Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2024.4381
Abstract: Key Points Question Does the addition of lenvatinib to ifosfamide and etoposide (IE) improve treatment outcomes in children and young adults with relapsed or refractory osteosarcoma? Findings In this randomized clinical trial including 81 patients,… read more here.
Keywords: young adults; lenvatinib plus; adults relapsed; plus ifosfamide ... See more keywords
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5483
Abstract: The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced renal cell carcinoma. This subset analysis investigated… read more here.
Keywords: sunitinib; plus pembrolizumab; pembrolizumab versus; lenvatinib plus ... See more keywords
Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5661
Abstract: Lenvatinib plus anti‐programmed death‐1 (anti‐PD‐1) antibody combinations have shown potent anti‐tumor effect in phase I/II trials in advanced or unresectable hepatocellular carcinoma (HCC), but real‐world data are limited. read more here.
Keywords: hepatocellular carcinoma; plus anti; programmed death; anti programmed ... See more keywords
The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2020.03.003
Abstract: BACKGROUND Patients with primary refractory metastatic renal cell carcinoma (mRCC) have a dismal prognosis and poor response to subsequent treatments. While there are several approved second-line therapies, it remains critical to choose the most effective… read more here.
Keywords: lenvatinib plus; line; plus everolimus; primary resistance ... See more keywords
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "European urology"
DOI: 10.1016/j.eururo.2021.03.015
Abstract: BACKGROUND Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with everolimus (an mTOR inhibitor) is approved for the treatment of advanced RCC after… read more here.
Keywords: lenvatinib plus; plus everolimus; study; single arm ... See more keywords
The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-97160-7
Abstract: To validate the efficacy and safety of thymosin α-1 combined with lenvatinib plus sintilimab in the treatment of unresectable hepatocellular carcinoma. Patients with unresectable hepatocellular carcinoma treated with lenvatinib plus sintilimab at the People’s Hospital… read more here.
Keywords: control; lenvatinib plus; group; unresectable hepatocellular ... See more keywords
Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "Liver Cancer"
DOI: 10.1159/000523849
Abstract: Introduction: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. Methods: This retrospective… read more here.
Keywords: hepatocellular carcinoma; drug eluting; lenvatinib; advanced hepatocellular ... See more keywords
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco-25-00748
Abstract: PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adenocarcinoma. METHODS Eligible participants 18 years and older with untreated human… read more here.
Keywords: pembrolizumab chemotherapy; lenvatinib plus; chemotherapy; plus pembrolizumab ... See more keywords
Second-line systematic strategy options for the progression of lenvatinib plus tislelizumab treating unresectable hepatocellular carcinoma: A retrospective study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e16135
Abstract: e16135 Background: Lenvatinib plus Tislelizumab (LEN+TIS) is a first-line systemic treatment for unresectable hepatocellular carcinoma (uHCC) in the real world, however, most uHCC ultimately fail to respond to first-line therapy due to tumor progression or… read more here.
Keywords: len tis; lenvatinib plus; group; first line ... See more keywords
LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.4095
Abstract: 4095 Background: LEAP-002 was a randomized, double-blind, phase 3 study (NCT03713593) that was conducted to evaluate the efficacy and safety of first-line lenvatinib plus pembrolizumab versus lenvatinib plus placebo in participants with advanced hepatocellular carcinoma… read more here.
Keywords: lenvatinib plus; pembrolizumab versus; plus pembrolizumab; lenvatinib ... See more keywords
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00221
Abstract: PURPOSE Effective treatments are needed for melanoma that progresses on inhibitors of programmed cell death protein-1 (PD-1) or its ligand (PD-L1). We conducted the phase II LEAP-004 study to evaluate the combination of the multikinase… read more here.
Keywords: plus pembrolizumab; inhibitor; death; melanoma confirmed ... See more keywords